Silence Therapeutics plc (SLN) 10-Year Financial Performance & Capital Metrics

SLN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

AboutSilence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.Show more

Revenue $43M +70.5%
EBITDA -$63M -27.7%
Net Income -$45M -4.7%
EPS (Diluted) -2.37 +31.9%
Gross Margin 72.7% +22.5%
EBITDA Margin -145% +25.1%
Operating Margin -146.38% +25.1%
Net Margin -104.74% +38.6%
ROE -58.08% +70.4%
ROIC -370.72%
Debt/Equity 0.00 -94.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 181.7%
✓Trading at only 0.6x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 24.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y121.82%

5Y181.67%

3Y51.6%

TTM27.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM-0.51%

ROCE

10Y Avg-49.18%

5Y Avg-62.24%

3Y Avg-57.45%

Latest-44.76%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	770K	16K	0	244K	5.48M	12.41M	21.66M	25.38M	43.26M
Revenue Growth %	-1%	-	-0.98%	-1%	-	21.45%	1.27%	0.74%	0.17%	0.7%
Cost of Goods Sold+	7.11M	8.71M	7.94M	9.74M	0	3.76M	7.46M	13.46M	10.32M	11.81M
COGS % of Revenue	-	11.31%	496.44%	-	-	0.69%	0.6%	0.62%	0.41%	0.27%
Gross Profit+	-7.11M	-7.94M	-7.93M	-9.74M	244K	1.72M	4.96M	8.19M	15.06M	31.45M
Gross Margin %	-	-10.31%	-495.44%	-	1%	0.31%	0.4%	0.38%	0.59%	0.73%
Gross Profit Growth %	0.2%	-0.12%	0%	-0.23%	1.03%	6.04%	1.89%	0.65%	0.84%	1.09%
Operating Expenses+	9.77M	12.68M	14.41M	20.57M	22.98M	37.56M	50.77M	69.23M	64.66M	94.77M
OpEx % of Revenue	-	16.46%	900.44%	-	94.17%	6.86%	4.09%	3.2%	2.55%	2.19%
Selling, General & Admin	2.65M	3.96M	6.46M	10.83M	9.64M	13.98M	20.01M	25.68M	20.64M	26.88M
SG&A % of Revenue	-	5.15%	404%	-	39.52%	2.55%	1.61%	1.19%	0.81%	0.62%
Research & Development	7.11M	8.71M	7.94M	9.74M	13.34M	20.21M	30.77M	43.55M	44.02M	67.88M
R&D % of Revenue	-	11.31%	496.44%	-	54.66%	3.69%	2.48%	2.01%	1.73%	1.57%
Other Operating Expenses	0	0	0	0	0	3.37M	0	0	0	0
Operating Income+	-9.77M	-11.91M	-14.39M	-20.57M	-22.73M	-35.85M	-45.81M	-61.04M	-49.6M	-63.32M
Operating Margin %	-	-15.46%	-899.44%	-	-93.17%	-6.54%	-3.69%	-2.82%	-1.95%	-1.46%
Operating Income Growth %	0.19%	-0.22%	-0.21%	-0.43%	-0.11%	-0.58%	-0.28%	-0.33%	0.19%	-0.28%
EBITDA+	-9.59M	-11.6M	-13.96M	-20.17M	-22.25M	-35.35M	-45.39M	-60.44M	-49.11M	-62.73M
EBITDA Margin %	-	-15.06%	-872.38%	-	-91.2%	-6.45%	-3.66%	-2.79%	-1.94%	-1.45%
EBITDA Growth %	0.19%	-0.21%	-0.2%	-0.45%	-0.1%	-0.59%	-0.28%	-0.33%	0.19%	-0.28%
D&A (Non-Cash Add-back)	182K	310K	433K	399K	482K	496K	427K	596K	498K	593K
EBIT	-9.77M	-11.91M	-3.76M	-20.57M	-22.84M	-36.02M	-45.85M	-61.04M	-50.28M	-49.58M
Net Interest Income+	175K	1.54M	-15K	39K	-6K	113K	2K	179K	1.41M	4.47M
Interest Income	175K	1.54M	0	39K	27K	129K	10K	226K	1.45M	4.47M
Interest Expense	0	0	15K	0	33K	16K	8K	47K	34K	0
Other Income/Expense	340K	1.54M	10.62M	45K	-136K	-194K	-42K	11.39M	-706K	18.86M
Pretax Income+	-9.43M	-10.36M	-3.77M	-20.53M	-22.87M	-36.04M	-45.86M	-49.65M	-50.31M	-44.46M
Pretax Margin %	-	-13.46%	-235.94%	-	-93.73%	-6.58%	-3.69%	-2.29%	-1.98%	-1.03%
Income Tax+	-2.78M	-1.92M	-2.16M	-2.12M	-3.29M	-3.49M	-6.45M	688K	-7.04M	845K
Effective Tax Rate %	0.7%	0.81%	0.43%	0.9%	0.86%	0.9%	0.86%	1.01%	0.86%	1.02%
Net Income+	-6.64M	-8.44M	-1.62M	-18.41M	-19.58M	-32.55M	-39.41M	-50.33M	-43.27M	-45.31M
Net Margin %	-	-10.96%	-101.13%	-	-80.25%	-5.94%	-3.17%	-2.32%	-1.71%	-1.05%
Net Income Growth %	0.4%	-0.27%	0.81%	-10.38%	-0.06%	-0.66%	-0.21%	-0.28%	0.14%	-0.05%
Net Income (Continuing)	-6.64M	-8.44M	-1.62M	-18.41M	-19.58M	-32.55M	-39.41M	-50.33M	-43.27M	-45.31M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.32	-0.40	-0.07	-0.83	-0.78	-1.12	-1.36	-3.81	-3.48	-2.37
EPS Growth %	0.53%	-0.25%	0.83%	-11.39%	0.06%	-0.44%	-0.21%	-1.8%	0.09%	0.32%
EPS (Basic)	-0.32	-0.40	-0.07	-0.83	-0.78	-1.12	-1.36	-3.81	-3.48	-2.37
Diluted Shares Outstanding	21.34M	23.27M	23.31M	23.44M	25.04M	27.26M	29.65M	10.73M	12.36M	15.42M
Basic Shares Outstanding	21.34M	23.27M	23.31M	23.44M	25.04M	27.26M	29.65M	10.73M	12.36M	15.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.55M	42.01M	45.55M	29.5M	37.47M	76.4M	86.33M	96.69M	103.15M	187.37M
Cash & Short-Term Investments	51.91M	39.01M	43.06M	26.54M	33.52M	37.45M	73.54M	71.14M	68.79M	147.33M
Cash Only	51.91M	39.01M	42.74M	21.49M	13.52M	27.45M	73.54M	54.82M	68.79M	121.33M
Short-Term Investments	0	0	319K	5.04M	20M	10M	0	16.33M	0	26M
Accounts Receivable	179K	810K	0	0	4K	29.31M	331K	915K	23.98M	26.91M
Days Sales Outstanding	-	383.96	-	-	5.98	1.95K	9.73	15.42	344.89	227.04
Inventory	-1.64M	-2.99M	-2.48M	-2.45M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.27M	1.9M	0	0	3.51M	5.7M	8.16M	16.43M	0	0
Total Non-Current Assets+	8M	13.78M	9.46M	9.39M	8.61M	9.57M	9.86M	10.81M	16.3M	15.27M
Property, Plant & Equipment	1.09M	1.38M	1.17M	921K	611K	1.13M	1.94M	2.2M	2.31M	1.98M
Fixed Asset Turnover	-	0.56x	0.01x	-	0.40x	4.86x	6.39x	9.84x	10.99x	21.90x
Goodwill	6.66M	7.71M	8.03M	8.13M	7.69M	8.13M	7.59M	8.01M	9.98M	9.39M
Intangible Assets	6K	45K	28K	64K	34K	17K	24K	320K	362K	312K
Long-Term Investments	0	4.42M	0	-4.77M	275K	303K	301K	284K	0	0
Other Non-Current Assets	233K	239K	233K	5.04M	0	0	0	0	3.65M	3.59M
Total Assets+	61.55M	55.79M	55.01M	38.88M	46.08M	85.97M	96.19M	107.5M	119.45M	202.63M
Asset Turnover	-	0.01x	0.00x	-	0.01x	0.06x	0.13x	0.20x	0.21x	0.21x
Asset Growth %	1.07%	-0.09%	-0.01%	-0.29%	0.18%	0.87%	0.12%	0.12%	0.11%	0.7%
Total Current Liabilities+	1.12M	1.61M	2.66M	3.83M	9.65M	25.57M	15.17M	21.94M	22.34M	16.82M
Accounts Payable	207K	528K	462K	1.15M	1.79M	2.29M	4.07M	3.19M	3.35M	3.7M
Days Payables Outstanding	10.62	22.12	21.23	42.97	-	221.7	199	86.38	118.44	114.26
Short-Term Debt	0	0	0	0	0	0	0	0	228K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K	306K
Other Current Liabilities	0	0	0	27K	2.48M	17.04M	4.43M	9.45M	8.58M	3.44M
Current Ratio	47.90x	26.09x	17.14x	7.70x	3.88x	2.99x	5.69x	4.41x	4.62x	11.14x
Quick Ratio	49.36x	27.95x	18.08x	8.34x	3.88x	2.99x	5.69x	4.41x	4.62x	11.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	207K	528K	462K	1.15M	15.52M	51.34M	72.5M	63.48M	75.12M	51.79M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	118K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	15.52M	51.34M	72.5M	63.48M	0	0
Total Liabilities	1.12M	1.61M	2.66M	3.83M	25.17M	76.91M	87.67M	85.43M	97.45M	68.61M
Total Debt+	0	0	0	0	287K	341K	137K	446K	346K	117K
Net Debt	-51.91M	-39.01M	-42.74M	-21.49M	-13.23M	-27.11M	-73.4M	-54.37M	-68.44M	-121.21M
Debt / Equity	-	-	-	-	0.01x	0.04x	0.02x	0.02x	0.02x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-959.40x	-	-688.91x	-2240.44x	-5726.75x	-1298.72x	-1458.94x	-
Total Equity+	60.43M	54.18M	52.35M	35.05M	20.91M	9.06M	8.53M	22.07M	21.99M	134.02M
Equity Growth %	1.18%	-0.1%	-0.03%	-0.33%	-0.4%	-0.57%	-0.06%	1.59%	-0%	5.09%
Book Value per Share	2.83	2.33	2.25	1.50	0.83	0.33	0.29	2.06	1.78	8.69
Total Shareholders' Equity	60.43M	54.18M	52.35M	35.05M	20.91M	9.06M	8.53M	22.07M	21.99M	134.02M
Common Stock	3.49M	3.49M	3.5M	3.55M	3.92M	4.17M	4.49M	5.39M	8.85M	10.29M
Retained Earnings	-109.44M	-115.95M	-116.43M	-133.78M	-152M	-184.22M	-222.97M	-263.26M	-431.89M	-474.04M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	166.37M	166.64M	165.28M	165.28M	30.84M	35.38M	42.67M	53.27M	40.36M	-11.78M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.26M	-10.07M	-9.6M	-16.76M	1.73M	-10.78M	9.19M	-57.04M	-39.35M	-67.64M
Operating CF Margin %	-	-13.07%	-599.94%	-	7.08%	-1.97%	0.74%	-2.63%	-1.55%	-1.56%
Operating CF Growth %	0.13%	-0.22%	0.05%	-0.75%	1.1%	-7.24%	1.85%	-7.21%	0.31%	-0.72%
Net Income	-9.43M	-10.36M	-3.77M	-20.53M	-22.87M	-36.04M	-61.89M	-50.33M	-50.31M	-36.19M
Depreciation & Amortization	182K	310K	433K	399K	482K	496K	576.29K	596K	498K	593K
Stock-Based Compensation	777K	475K	638K	681K	584K	4.39M	11.65M	12.69M	13.05M	13.03M
Deferred Taxes	1.51M	1.59M	-8.4M	1.82M	2.31M	3.02M	5.95M	688K	0	845K
Other Non-Cash Items	-175K	-1.54M	-206K	-45K	136K	-1.3M	468.32K	-1.28M	9.07M	-12.89M
Working Capital Changes	-1.12M	-539K	1.71M	913K	21.09M	18.66M	52.43M	-19.4M	-11.66M	-33.02M
Change in Receivables	-228K	-1.03M	664K	691K	-4K	-29.3M	37.09M	-10.54M	314K	-904K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	4.33M	-4.67M	13.01M	-4.83M	-15.02M	9.62M	11.71M	-20.5M	16.43M	-21.97M
Capital Expenditures	-850K	-537K	-173K	-188K	-9K	-511K	-1.77M	-173K	-45K	-211K
CapEx % of Revenue	-	0.7%	10.81%	-	0.04%	0.09%	0.14%	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	175K	161K	13.2M	97K	-6K	129K	-17.55K	-372K	958K	117.41M
Cash from Financing+	39.15M	-101K	48K	341K	5.27M	15.43M	41.45M	52.58M	25.16M	142.09M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-101K	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.11M	-10.6M	-9.77M	-16.95M	1.72M	-11.29M	7.39M	-57.59M	-39.4M	-67.85M
FCF Margin %	-	-13.77%	-610.75%	-	7.04%	-2.06%	0.59%	-2.66%	-1.55%	-1.57%
FCF Growth %	0.07%	-0.16%	0.08%	-0.73%	1.1%	-7.57%	1.65%	-8.8%	0.32%	-0.72%
FCF per Share	-0.43	-0.46	-0.42	-0.72	0.07	-0.41	0.25	-5.37	-3.19	-4.40
FCF Conversion (FCF/Net Income)	1.24x	1.19x	5.93x	0.91x	-0.09x	0.33x	-0.23x	1.13x	0.91x	1.49x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	433K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-15.07%	-14.73%	-3.04%	-42.13%	-69.98%	-217.21%	-448.22%	-329%	-196.38%	-58.08%
Return on Invested Capital (ROIC)	-75.45%	-75.38%	-87.12%	-133.2%	-160.54%	-	-	-	-	-370.72%
Gross Margin	-	-1031.3%	-49543.75%	-	100%	31.34%	39.94%	37.83%	59.34%	72.7%
Net Margin	-	-1096.1%	-10112.5%	-	-8025.41%	-594.03%	-317.44%	-232.44%	-170.51%	-104.74%
Debt / Equity	-	-	-	-	0.01x	0.04x	0.02x	0.02x	0.02x	0.00x
Interest Coverage	-	-	-959.40x	-	-688.91x	-2240.44x	-5726.75x	-1298.72x	-1458.94x	-
FCF Conversion	1.24x	1.19x	5.93x	0.91x	-0.09x	0.33x	-0.23x	1.13x	0.91x	1.49x
Revenue Growth	-100%	-	-97.92%	-100%	-	2145.49%	126.59%	74.43%	17.18%	70.47%

Revenue by Segment

	2021	2022	2023	2024
Research Collaboration Income	12.02M	16.9M	24.8M	43.1M
Research Collaboration Income Growth	-	40.56%	46.75%	73.79%
Royalty Income	392K	600K	600K	100K
Royalty Income Growth	-	53.06%	0.00%	-83.33%

Revenue by Geography

	2021	2022	2023	2024
GERMANY	392K	578K	569K	144K
GERMANY Growth	-	47.45%	-1.56%	-74.69%

Frequently Asked Questions

Growth & Financials

Silence Therapeutics plc (SLN) reported $24.9M in revenue for fiscal year 2024. This represents a 3481% increase from $0.7M in 2011.

Silence Therapeutics plc (SLN) grew revenue by 70.5% over the past year. This is strong growth.

Silence Therapeutics plc (SLN) reported a net loss of $62.7M for fiscal year 2024.

Dividend & Returns

Silence Therapeutics plc (SLN) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.

Silence Therapeutics plc (SLN) had negative free cash flow of $70.0M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Silence Therapeutics plc (SLN) 10-Year Financial Performance & Capital Metrics

SLN • • Industrial / General

HealthcareBiotechnologyRare Genetic DiseasesGene Therapy & Rare Diseases

Revenue $43M +70.5%
EBITDA -$63M -27.7%
Net Income -$45M -4.7%
EPS (Diluted) -2.37 +31.9%
Gross Margin 72.7% +22.5%
EBITDA Margin -145% +25.1%
Operating Margin -146.38% +25.1%
Net Margin -104.74% +38.6%
ROE -58.08% +70.4%
ROIC -370.72%
Debt/Equity 0.00 -94.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 181.7%
✓Trading at only 0.6x book value

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 24.7% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y121.82%

5Y181.67%

3Y51.6%

TTM27.2%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-5.68%

EPS CAGR

10Y-

5Y-

3Y-

TTM-0.51%

ROCE

10Y Avg-49.18%

5Y Avg-62.24%

3Y Avg-57.45%

Latest-44.76%

Peer Comparison

Gene Therapy & Rare Diseases

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
KRYSKrystal Biotech, Inc.	8.18B	282.01	94.00	473.02%	53.3%	17.48%	1.46%	0.01
BMRNBioMarin Pharmaceutical Inc.	10.58B	55.07	24.92	17.97%	16.82%	8.59%	4.49%	0.11
SRPTSarepta Therapeutics, Inc.	2.23B	21.31	9.11	52.97%	-11.25%	-20.57%		0.88
RAREUltragenyx Pharmaceutical Inc.	2.27B	23.50	-3.74	29.01%	-91.95%	-35.88%		0.15
DYNDyne Therapeutics, Inc.	2.7B	16.42	-4.87			-61.26%		0.04
TVTXTravere Therapeutics, Inc.	2.54B	28.40	-6.96	60.55%	-20.32%	-120.36%		6.80
BEAMBeam Therapeutics Inc.	3.25B	32.05	-7.00	-83.18%	-7.44%	-42.92%		0.22
SLNOSoleno Therapeutics, Inc.	2.25B	41.95	-9.58		-79.5%	-15.85%		0.22

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	770K	16K	0	244K	5.48M	12.41M	21.66M	25.38M	43.26M
Revenue Growth %	-1%	-	-0.98%	-1%	-	21.45%	1.27%	0.74%	0.17%	0.7%
Cost of Goods Sold+	7.11M	8.71M	7.94M	9.74M	0	3.76M	7.46M	13.46M	10.32M	11.81M
COGS % of Revenue	-	11.31%	496.44%	-	-	0.69%	0.6%	0.62%	0.41%	0.27%
Gross Profit+	-7.11M	-7.94M	-7.93M	-9.74M	244K	1.72M	4.96M	8.19M	15.06M	31.45M
Gross Margin %	-	-10.31%	-495.44%	-	1%	0.31%	0.4%	0.38%	0.59%	0.73%
Gross Profit Growth %	0.2%	-0.12%	0%	-0.23%	1.03%	6.04%	1.89%	0.65%	0.84%	1.09%
Operating Expenses+	9.77M	12.68M	14.41M	20.57M	22.98M	37.56M	50.77M	69.23M	64.66M	94.77M
OpEx % of Revenue	-	16.46%	900.44%	-	94.17%	6.86%	4.09%	3.2%	2.55%	2.19%
Selling, General & Admin	2.65M	3.96M	6.46M	10.83M	9.64M	13.98M	20.01M	25.68M	20.64M	26.88M
SG&A % of Revenue	-	5.15%	404%	-	39.52%	2.55%	1.61%	1.19%	0.81%	0.62%
Research & Development	7.11M	8.71M	7.94M	9.74M	13.34M	20.21M	30.77M	43.55M	44.02M	67.88M
R&D % of Revenue	-	11.31%	496.44%	-	54.66%	3.69%	2.48%	2.01%	1.73%	1.57%
Other Operating Expenses	0	0	0	0	0	3.37M	0	0	0	0
Operating Income+	-9.77M	-11.91M	-14.39M	-20.57M	-22.73M	-35.85M	-45.81M	-61.04M	-49.6M	-63.32M
Operating Margin %	-	-15.46%	-899.44%	-	-93.17%	-6.54%	-3.69%	-2.82%	-1.95%	-1.46%
Operating Income Growth %	0.19%	-0.22%	-0.21%	-0.43%	-0.11%	-0.58%	-0.28%	-0.33%	0.19%	-0.28%
EBITDA+	-9.59M	-11.6M	-13.96M	-20.17M	-22.25M	-35.35M	-45.39M	-60.44M	-49.11M	-62.73M
EBITDA Margin %	-	-15.06%	-872.38%	-	-91.2%	-6.45%	-3.66%	-2.79%	-1.94%	-1.45%
EBITDA Growth %	0.19%	-0.21%	-0.2%	-0.45%	-0.1%	-0.59%	-0.28%	-0.33%	0.19%	-0.28%
D&A (Non-Cash Add-back)	182K	310K	433K	399K	482K	496K	427K	596K	498K	593K
EBIT	-9.77M	-11.91M	-3.76M	-20.57M	-22.84M	-36.02M	-45.85M	-61.04M	-50.28M	-49.58M
Net Interest Income+	175K	1.54M	-15K	39K	-6K	113K	2K	179K	1.41M	4.47M
Interest Income	175K	1.54M	0	39K	27K	129K	10K	226K	1.45M	4.47M
Interest Expense	0	0	15K	0	33K	16K	8K	47K	34K	0
Other Income/Expense	340K	1.54M	10.62M	45K	-136K	-194K	-42K	11.39M	-706K	18.86M
Pretax Income+	-9.43M	-10.36M	-3.77M	-20.53M	-22.87M	-36.04M	-45.86M	-49.65M	-50.31M	-44.46M
Pretax Margin %	-	-13.46%	-235.94%	-	-93.73%	-6.58%	-3.69%	-2.29%	-1.98%	-1.03%
Income Tax+	-2.78M	-1.92M	-2.16M	-2.12M	-3.29M	-3.49M	-6.45M	688K	-7.04M	845K
Effective Tax Rate %	0.7%	0.81%	0.43%	0.9%	0.86%	0.9%	0.86%	1.01%	0.86%	1.02%
Net Income+	-6.64M	-8.44M	-1.62M	-18.41M	-19.58M	-32.55M	-39.41M	-50.33M	-43.27M	-45.31M
Net Margin %	-	-10.96%	-101.13%	-	-80.25%	-5.94%	-3.17%	-2.32%	-1.71%	-1.05%
Net Income Growth %	0.4%	-0.27%	0.81%	-10.38%	-0.06%	-0.66%	-0.21%	-0.28%	0.14%	-0.05%
Net Income (Continuing)	-6.64M	-8.44M	-1.62M	-18.41M	-19.58M	-32.55M	-39.41M	-50.33M	-43.27M	-45.31M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.32	-0.40	-0.07	-0.83	-0.78	-1.12	-1.36	-3.81	-3.48	-2.37
EPS Growth %	0.53%	-0.25%	0.83%	-11.39%	0.06%	-0.44%	-0.21%	-1.8%	0.09%	0.32%
EPS (Basic)	-0.32	-0.40	-0.07	-0.83	-0.78	-1.12	-1.36	-3.81	-3.48	-2.37
Diluted Shares Outstanding	21.34M	23.27M	23.31M	23.44M	25.04M	27.26M	29.65M	10.73M	12.36M	15.42M
Basic Shares Outstanding	21.34M	23.27M	23.31M	23.44M	25.04M	27.26M	29.65M	10.73M	12.36M	15.42M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.55M	42.01M	45.55M	29.5M	37.47M	76.4M	86.33M	96.69M	103.15M	187.37M
Cash & Short-Term Investments	51.91M	39.01M	43.06M	26.54M	33.52M	37.45M	73.54M	71.14M	68.79M	147.33M
Cash Only	51.91M	39.01M	42.74M	21.49M	13.52M	27.45M	73.54M	54.82M	68.79M	121.33M
Short-Term Investments	0	0	319K	5.04M	20M	10M	0	16.33M	0	26M
Accounts Receivable	179K	810K	0	0	4K	29.31M	331K	915K	23.98M	26.91M
Days Sales Outstanding	-	383.96	-	-	5.98	1.95K	9.73	15.42	344.89	227.04
Inventory	-1.64M	-2.99M	-2.48M	-2.45M	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.27M	1.9M	0	0	3.51M	5.7M	8.16M	16.43M	0	0
Total Non-Current Assets+	8M	13.78M	9.46M	9.39M	8.61M	9.57M	9.86M	10.81M	16.3M	15.27M
Property, Plant & Equipment	1.09M	1.38M	1.17M	921K	611K	1.13M	1.94M	2.2M	2.31M	1.98M
Fixed Asset Turnover	-	0.56x	0.01x	-	0.40x	4.86x	6.39x	9.84x	10.99x	21.90x
Goodwill	6.66M	7.71M	8.03M	8.13M	7.69M	8.13M	7.59M	8.01M	9.98M	9.39M
Intangible Assets	6K	45K	28K	64K	34K	17K	24K	320K	362K	312K
Long-Term Investments	0	4.42M	0	-4.77M	275K	303K	301K	284K	0	0
Other Non-Current Assets	233K	239K	233K	5.04M	0	0	0	0	3.65M	3.59M
Total Assets+	61.55M	55.79M	55.01M	38.88M	46.08M	85.97M	96.19M	107.5M	119.45M	202.63M
Asset Turnover	-	0.01x	0.00x	-	0.01x	0.06x	0.13x	0.20x	0.21x	0.21x
Asset Growth %	1.07%	-0.09%	-0.01%	-0.29%	0.18%	0.87%	0.12%	0.12%	0.11%	0.7%
Total Current Liabilities+	1.12M	1.61M	2.66M	3.83M	9.65M	25.57M	15.17M	21.94M	22.34M	16.82M
Accounts Payable	207K	528K	462K	1.15M	1.79M	2.29M	4.07M	3.19M	3.35M	3.7M
Days Payables Outstanding	10.62	22.12	21.23	42.97	-	221.7	199	86.38	118.44	114.26
Short-Term Debt	0	0	0	0	0	0	0	0	228K	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	1000K	306K
Other Current Liabilities	0	0	0	27K	2.48M	17.04M	4.43M	9.45M	8.58M	3.44M
Current Ratio	47.90x	26.09x	17.14x	7.70x	3.88x	2.99x	5.69x	4.41x	4.62x	11.14x
Quick Ratio	49.36x	27.95x	18.08x	8.34x	3.88x	2.99x	5.69x	4.41x	4.62x	11.14x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	207K	528K	462K	1.15M	15.52M	51.34M	72.5M	63.48M	75.12M	51.79M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	118K	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	15.52M	51.34M	72.5M	63.48M	0	0
Total Liabilities	1.12M	1.61M	2.66M	3.83M	25.17M	76.91M	87.67M	85.43M	97.45M	68.61M
Total Debt+	0	0	0	0	287K	341K	137K	446K	346K	117K
Net Debt	-51.91M	-39.01M	-42.74M	-21.49M	-13.23M	-27.11M	-73.4M	-54.37M	-68.44M	-121.21M
Debt / Equity	-	-	-	-	0.01x	0.04x	0.02x	0.02x	0.02x	0.00x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-959.40x	-	-688.91x	-2240.44x	-5726.75x	-1298.72x	-1458.94x	-
Total Equity+	60.43M	54.18M	52.35M	35.05M	20.91M	9.06M	8.53M	22.07M	21.99M	134.02M
Equity Growth %	1.18%	-0.1%	-0.03%	-0.33%	-0.4%	-0.57%	-0.06%	1.59%	-0%	5.09%
Book Value per Share	2.83	2.33	2.25	1.50	0.83	0.33	0.29	2.06	1.78	8.69
Total Shareholders' Equity	60.43M	54.18M	52.35M	35.05M	20.91M	9.06M	8.53M	22.07M	21.99M	134.02M
Common Stock	3.49M	3.49M	3.5M	3.55M	3.92M	4.17M	4.49M	5.39M	8.85M	10.29M
Retained Earnings	-109.44M	-115.95M	-116.43M	-133.78M	-152M	-184.22M	-222.97M	-263.26M	-431.89M	-474.04M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	166.37M	166.64M	165.28M	165.28M	30.84M	35.38M	42.67M	53.27M	40.36M	-11.78M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-8.26M	-10.07M	-9.6M	-16.76M	1.73M	-10.78M	9.19M	-57.04M	-39.35M	-67.64M
Operating CF Margin %	-	-13.07%	-599.94%	-	7.08%	-1.97%	0.74%	-2.63%	-1.55%	-1.56%
Operating CF Growth %	0.13%	-0.22%	0.05%	-0.75%	1.1%	-7.24%	1.85%	-7.21%	0.31%	-0.72%
Net Income	-9.43M	-10.36M	-3.77M	-20.53M	-22.87M	-36.04M	-61.89M	-50.33M	-50.31M	-36.19M
Depreciation & Amortization	182K	310K	433K	399K	482K	496K	576.29K	596K	498K	593K
Stock-Based Compensation	777K	475K	638K	681K	584K	4.39M	11.65M	12.69M	13.05M	13.03M
Deferred Taxes	1.51M	1.59M	-8.4M	1.82M	2.31M	3.02M	5.95M	688K	0	845K
Other Non-Cash Items	-175K	-1.54M	-206K	-45K	136K	-1.3M	468.32K	-1.28M	9.07M	-12.89M
Working Capital Changes	-1.12M	-539K	1.71M	913K	21.09M	18.66M	52.43M	-19.4M	-11.66M	-33.02M
Change in Receivables	-228K	-1.03M	664K	691K	-4K	-29.3M	37.09M	-10.54M	314K	-904K
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	4.33M	-4.67M	13.01M	-4.83M	-15.02M	9.62M	11.71M	-20.5M	16.43M	-21.97M
Capital Expenditures	-850K	-537K	-173K	-188K	-9K	-511K	-1.77M	-173K	-45K	-211K
CapEx % of Revenue	-	0.7%	10.81%	-	0.04%	0.09%	0.14%	0.01%	0%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	175K	161K	13.2M	97K	-6K	129K	-17.55K	-372K	958K	117.41M
Cash from Financing+	39.15M	-101K	48K	341K	5.27M	15.43M	41.45M	52.58M	25.16M	142.09M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-101K	0	0	0	0	0	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.11M	-10.6M	-9.77M	-16.95M	1.72M	-11.29M	7.39M	-57.59M	-39.4M	-67.85M
FCF Margin %	-	-13.77%	-610.75%	-	7.04%	-2.06%	0.59%	-2.66%	-1.55%	-1.57%
FCF Growth %	0.07%	-0.16%	0.08%	-0.73%	1.1%	-7.57%	1.65%	-8.8%	0.32%	-0.72%
FCF per Share	-0.43	-0.46	-0.42	-0.72	0.07	-0.41	0.25	-5.37	-3.19	-4.40
FCF Conversion (FCF/Net Income)	1.24x	1.19x	5.93x	0.91x	-0.09x	0.33x	-0.23x	1.13x	0.91x	1.49x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	433K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-15.07%	-14.73%	-3.04%	-42.13%	-69.98%	-217.21%	-448.22%	-329%	-196.38%	-58.08%
Return on Invested Capital (ROIC)	-75.45%	-75.38%	-87.12%	-133.2%	-160.54%	-	-	-	-	-370.72%
Gross Margin	-	-1031.3%	-49543.75%	-	100%	31.34%	39.94%	37.83%	59.34%	72.7%
Net Margin	-	-1096.1%	-10112.5%	-	-8025.41%	-594.03%	-317.44%	-232.44%	-170.51%	-104.74%
Debt / Equity	-	-	-	-	0.01x	0.04x	0.02x	0.02x	0.02x	0.00x
Interest Coverage	-	-	-959.40x	-	-688.91x	-2240.44x	-5726.75x	-1298.72x	-1458.94x	-
FCF Conversion	1.24x	1.19x	5.93x	0.91x	-0.09x	0.33x	-0.23x	1.13x	0.91x	1.49x
Revenue Growth	-100%	-	-97.92%	-100%	-	2145.49%	126.59%	74.43%	17.18%	70.47%

Revenue by Segment

	2021	2022	2023	2024
Research Collaboration Income	12.02M	16.9M	24.8M	43.1M
Research Collaboration Income Growth	-	40.56%	46.75%	73.79%
Royalty Income	392K	600K	600K	100K
Royalty Income Growth	-	53.06%	0.00%	-83.33%

Revenue by Geography

	2021	2022	2023	2024
GERMANY	392K	578K	569K	144K
GERMANY Growth	-	47.45%	-1.56%	-74.69%

Frequently Asked Questions

Growth & Financials

Silence Therapeutics plc (SLN) reported $24.9M in revenue for fiscal year 2024. This represents a 3481% increase from $0.7M in 2011.

Silence Therapeutics plc (SLN) grew revenue by 70.5% over the past year. This is strong growth.

Silence Therapeutics plc (SLN) reported a net loss of $62.7M for fiscal year 2024.

Dividend & Returns

Silence Therapeutics plc (SLN) has a return on equity (ROE) of -58.1%. Negative ROE indicates the company is unprofitable.

Silence Therapeutics plc (SLN) had negative free cash flow of $70.0M in fiscal year 2024, likely due to heavy capital investments.